EUVIMEDEUVIMED entdecken
Crossref

Association of RNF43 Genetic Alterations With BRAF V600E and MSI high in Colorectal Cancer

Arndt Vogel iD, Karthikeyan Murugesan iD, Gajanan Kendre iD, Julia C F Quintanilha, Jeffrey S Ross iD, Tilman Brummer iD, Anna Saborowski iD

JCO Precision Oncology · 2024

DOI: 10.1200/po.23.00411 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Arndt Vogel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Toronto General Hospital, Princess Margaret Cancer Centre, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Colorectal Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Recent studies have provided evidence for a predictive value of RNF43 genetic alterations (GAs) as biomarkers for targeted therapies in microsatellite-stable (MSS) colorectal cancer (CRC). These data have the potential to prioritize treatment strategies in patients with BRAF V600E -mutant CRC and help to identify a subgroup that is more likely to derive benefit versus those patients for whom alternative treatment approaches are needed. We were therefore interested in defining the precise frequency of BRAF V600E and RNF43 GAs and their respective overlap in a large cohort of patients with CRC. METHODS To address this question, we performed a retrospective analysis that included 52,969 patients diagnosed with CRC from the FoundationCORE database. RESULTS We observed a striking association of RNF43 GAs with MSI and tumor mutational burden status and BRAF V600E mutations. Overall, 23% of MSS patients with confirmed BRAF V600E mutation harbor an RNF43 GA—which accounts for 1.1% of all patients with CRC and for 15.7% of all CRC BRAF V600E cases. CONCLUSION Ongoing phase III clinical trials, such as BREAKWATER, should aim to incorporate broader genetic profiling to further validate the superior sensitivity of patients with RNF43-mutant, MSS BRAF V600E CRC to anti–EGFR-/BRAFi-based therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafColorectal NeoplasmsHumansRetrospective StudiesMicrosatellite InstabilityMutationUbiquitin-Protein Ligases

Substanzen

Proto-Oncogene Proteins B-rafBRAF protein, humanRNF43 protein, humanUbiquitin-Protein Ligases

Autor:innen und Institutionen

  • Toronto General Hospital, Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Hannover Medical School, Hannover, Germany.
  • Foundation Medicine, Inc, Cambridge, MA.
  • Department of Life Science, National Institute of Technology Rourkela (NITR), Rourkela, India.
  • Institute of Molecular Medicine and Cell Research, ZBMZ, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • German Cancer Consortium (DKTK), Partner Site Freiburg and German Cancer Research Center (DKFZ), Heidelberg, Germany.

ORCID-Profile: Arndt Vogel, Karthikeyan Murugesan, Gajanan Kendre, Jeffrey S Ross, Tilman Brummer, Anna Saborowski

Zitieren

APA

Vogel, A., Murugesan, K., Kendre, G., Quintanilha, J. C. F., Ross, J. S., Brummer, T., & Saborowski, A. (2024). Association of RNF43 Genetic Alterations With BRAF V600E and MSI high in Colorectal Cancer. JCO Precision Oncology. https://doi.org/10.1200/po.23.00411

Vancouver

Vogel A, Murugesan K, Kendre G, Quintanilha JCF, Ross JS, Brummer T, et al. Association of RNF43 Genetic Alterations With BRAF V600E and MSI high in Colorectal Cancer. JCO Precision Oncology. 2024. doi:10.1200/po.23.00411

BibTeX
@article{Vogel2024,
  author = {Vogel, Arndt and Murugesan, Karthikeyan and Kendre, Gajanan and Quintanilha, Julia C F and Ross, Jeffrey S and Brummer, Tilman and Saborowski, Anna},
  title = {Association of RNF43 Genetic Alterations With BRAF V600E and MSI high in Colorectal Cancer},
  journal = {JCO Precision Oncology},
  year = {2024},
  doi = {10.1200/po.23.00411}
}
Kostenlos starten →